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A B S T R A C T
Melanoma causes substantial burden of medical costs and years of life lost. Wide variations in melanoma di-
agnosis and treatment have been identified at least in the United States, Australia, Germany, Italy and France
[1]. The variation especially in the quality of reporting on pathological specimens has been reported. The aim of
this retrospective study was to assess the impact of expert pathology review of melanoma on the staging and thus
treatment decisions in cutaneous melanoma patients in a multidisciplinary tumor board.
A total of 567 patients were referred to the multidisciplinary meeting with a diagnosis of new invasive or in
situ melanoma from 14.10.2014 to 31.5.2018. Among these patients, a second expert histopathologic review
resulted in changes in interpretation for 46 out of 567 (8%) patients. Of patients originally diagnosed with
melanoma, pathologic review led to a change in diagnosis to benign lesions in 19 cases. The Breslow thickness
changed>0.3mm in 22 cases leading changes in staging and thus treatment. Minor changes (≤0.3mm) in
Breslow thickness was found in 5 cases.
Our data suggest that review of melanoma by an expert dermatopathologist results in frequent, clinically
meaningful alterations in diagnosis, staging and surgical treatment. The confirmation of a cancer diagnosis
should be the first step in the initiation of multidisciplinary monitoring especially in patients younger than 40
years old and early-stage tumors.
1. Introduction
Wide variations in melanoma diagnosis and treatment have been
identified around the world, which has prompted concerns about
equitable and timely treatment [1]. Review of histopathologic material
by an expert dermatopathologist ensures that appropriate treatment is
selected based on the preoperative assessment of pathology results [2].
Especially, review of early-stage melanoma histopathologic material
may be of particular benefit to establish correct diagnosis. This in-
formation is critical because it defines the recommended surgical
management for early-stage melanoma according to guidelines [3].
A trend towards thinner and less invasive melanomas has been
observed during recent decades in both central Europe and Australia
[4]. Of new cases diagnosed, 70% are thin melanomas (≤1mm) [5]. In
a statement of European partnership action against cancer consensus
group (EPAAC) (2014), it was recommended that multidisciplinary
teams (MDT) should monitor all new and recurrent cancer patients, and
every case should be presented at a tumor board [2]. According to
European cancer organization essential requirements for quality cancer
care (ERQCC) (2018), early-stage melanoma lesions can be managed by
a local dermatology unit that does not have the MDT, while all ad-
vanced cases should be seen in specialist melanoma centre [6]. Review
of histopathologic material by an expert dermatopathologist is com-
monly performed in MDTs [3].
In our clinic the multidisciplinary melanoma meetings have been
performed since 14th October 2014. In this retrospective study the
impact of a second expert pathology review on the staging and thus
treatment decisions in cutaneous melanoma patients in a Finnish re-
gional university hospital population cohort was evaluated.
2. Materials and methods
A retrospective analysis was carried out reviewing the patient re-
cords of cutaneous melanoma cases assessed in the multidisciplinary
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cutaneous melanoma meeting from 14.10.2014 to 31.5.2018 in a
Finnish regional university hospital (Tampere university hospital, the
region's largest hospital and the tertiary referral centre of Pirkanmaa).
The population in the Pirkanmaa region was 509 356 at the end of the
study. In this study we sought to determine the impact of a second
expert pathology review on the staging and treatment decisions in cu-
taneous melanoma patients. In addition, we also wanted to find out
whether patient's age, gender or tumor Breslow thickness has the con-
nection with changes in pathology review. Patients referred to the
multidisciplinary meeting with a diagnosis of new invasive or new in
situ melanoma were included in the study. Recurrent melanomas were
excluded. In our hospital all invasive cutaneous melanomas in head and
neck area are treated at the head and neck clinic with their own MDT
and were not included in this study.
All medical records and the initial pathology report are sent from
the referral centre (local dermatology clinic) to dermatologists and
plastic surgeons at our skin cancer unit. An initial treatment plan is
formulated prior to the MDT meeting. The original pathology slides are
sent for expert pathology review. Slides are double read independently
by two dermatopathologists blinded to the original pathology inter-
pretation and the consensus is recorded. A final treatment plan in-
formed by the expert pathology review is made at the MDT according to
international current clinical guideline.
Permission to access the clinical records of the melanoma patients
for the study was obtained from the scientific centre of Tampere uni-
versity hospital. Using the patients’ social security number, the clinical
records of all patients were reviewed. The age and gender of the patient
were recorded as well as location and Breslow thickness of the tumor.
Changes in a second expert histopathologic review were categorized as
follows: the diagnosis changed from malignant to benign, Breslow
thickness changed>0.3mm, Breslow thickness changed ≤0.3mm.
3. Statistical analysis
Differences between men and women were described by number of
cases with percentages. Median age and median Breslow thickness were
calculated.
4. Results
A total of 594 patients (women n=280, men n= 314) were re-
ferred to the multidisciplinary meeting with a diagnosis of invasive, in
situ (MIS) or recurrent melanoma from 14.10.2014 to 31.5.2018. Of
these melanomas, 27 (women n=12, men n= 15) were recurrent
melanomas and were excluded, leaving 567 (women n=268, men
n=299) patients in the study. Of these melanomas, 20% (121/567)
were in situ melanomas and 80% (446/567) were invasive melanomas.
The biopsy type was excisional in 88% (n=501) of cases and punch
biopsy in 12% (n=66) of cases. The median age of patients was 67
years (IQR 54–75) and the median Breslow thickness of melanomas was
0.8 mm (min 0, max 17mm). Among these patients, a second expert
histopathologic review resulted in changes in interpretation for 8%
(46/567) of patients (women n=35, men n=11). The flow diagram
for the full sample is presented in Table 1. A change in diagnosis oc-
curred in 11% (13/121) of those with in situ melanoma diagnoses at
baseline, and in 7% (33/446) of those diagnosed with invasive mela-
noma at baseline. Furthermore, change in tumor stage occurred in 3%
(16/567) of all patients. The median age of patients with mis-
classification was 57 years (IQR 38–71). The median Breslow thickness
of melanomas with misclassification (initial diagnosis) was 0.96mm
(min 0, max 6mm).
Of patients originally diagnosed with melanoma, pathologic review
led to a change in diagnosis to benign lesions in 3% (19/567) cases. In
these cases, the median age was younger; 36 years (IQR 27–43).
Changes from malignant to benign was more common in women
(6%,15/268) than in men (1%, 4/299). The changed diagnosis was
most commonly Spitz nevus (n=11), compound nevus (n=6) and
blue nevus (n=2). The median Breslow thickness in these tumors
(initial diagnosis) was 1.1 mm (min 0, max 3). Misclassification was not
associated with location of the tumor. To nine of these 19 patients a
sentinel node biopsy (SNB) would have been performed combined to re-
excision according to first diagnosis. The detailed data is presented in
Table 2.
The Breslow thickness changed > 0.3mm in 5% (22/446) of cases
(women n=13, men n=9) leading changes in staging and thus
treatment in 9 cases. The median age of these patients was 65 years
(IQR 52–74) and the median Breslow thickness (initial diagnosis) was
0.92mm (min 0, max 6). Minor change (≤0.3mm) in Breslow thick-
ness was found in 5 cases (women n=3, men n=2). The median age
of these patients was 83 years (IQR 63–85) and the median Breslow
thickness was 0.3 mm (min 0, max 0.3). Changes in Breslow thickness
are presented in Table 3.
Staging did not change in 2% (11/567) of cases. Fifteen out of 27
patients (56%) were upstaged; reasons for upstaging included findings
of higher Breslow thickness or ulceration. The most of changes were
seen in MIS, as nine cases with an outside diagnosis of MIS were up-
staged to invasive melanoma. The detailed data of changes is staging
are presented in Table 4a and b.
Table 1
Flow diagram for the full sample.
Table 2
Change from malignant to benign.
1st diagnosis/Breslow
thickness (mm)
Diagnosis after 2nd
review
Age (years) Location
Women (n=15, 5%)
1.0 Spitz nevus 39 thigh
in situ Spitz nevus 16 thigh
1.5 Compound nevus 37 foot
3.0 Spitz nevus 40 leg
in situ Compound nevus 39 shoulder
0.9 Spitz nevus 37 arm
0.4 Compound nevus 47 arm
2.0 Blue nevus 30 buttock
1.4 Spitz nevus 29 back
0.5 Spitz nevus 36 back
1.2 Spitz nevus 22 foot
in situ Spitz nevus 56 back
0.7 Spitz nevus 20 knee
in situ Compound nevus 28 abdomen
1.4 Blue nevus 29 back
Men (n=4, 1%)
1.8 Compound nevus 35 toe
0.5 Spitz nevus 42 arm
0.6 Spitz nevus 43 chest wall
0.5 Compound nevus 30 chest wall
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5. Discussion
This study shows that review of melanoma by an expert
dermatopathologist results in frequent and clinically meaningful al-
terations in diagnosis, staging and surgical treatment in cutaneous
melanoma patients. This is in agreement with earlier study by Suzuki
et al. (2018), whose findings suggested that second opinion by pa-
thologists trained in melanocytic lesions is likely to show significant
differences from the original report [7]. Although the rate of agreement
with the referring diagnoses is quite high, misdiagnosing can result in
unnecessary psychological distress and over or under treatment to the
part of the patients. This possibility of mistreating according to initial
diagnosis was also found in this study. Using tumor thickness as criteria
for SNB, we identified that using a tumor thickness ≥0.8mm, a change
in recommendation in SNB was observed in 12 out of 27 cases. Fur-
thermore, to nine out of 19 patients whose referral diagnosis of mela-
noma changed to benign SNB would have been performed combined to
re-excision according to the initial diagnosis.
In addition to assess the impact of expert pathology review of
melanoma on the staging and treatment decisions, we also wanted to
find out whether patient's age, gender or Breslow thickness of the tumor
have the connection with changes in pathology review. The importance
of a second expert histopathology review especially in difficult pig-
mented lesions in the group of young patients younger than 20 years of
age has been presented earlier [8]. We found that the median age (36 y)
in the patients whose diagnosis changed from malignant to benign was
lower than in patients with changed diagnosis (57y) or patients with
changes in the Breslow thickness of the tumor (> 0.3mm, 65 y and
≤0.3, 83 y). Change in diagnosis was also more common in women
than in men. Of patients originally diagnosed with melanoma, patho-
logic review led most commonly to a change in diagnosis to Spitz nevus.
This could be explained by the fact that some benign melanocytic le-
sions exhibit a wide spectrum of atypical histologic features simulating
melanoma and are more frequent in younger patients [3]. The identi-
fication of this subset of patients who are at particular risk of mis-
diagnosis strongly supports the concept of referral of younger mela-
noma patients to a multidisciplinary tumor board.
The changes in diagnosis especially in early-stage melanomas have
also been seen in earlier studies but the impact of expert pathology
review has not been quantified [3]. In this study, the median Breslow
thickness in tumors with changed diagnosis showed that most of the
tumors were early-stage melanomas. Our data also revealed that the
most of changes were seen in in situ melanomas. The review of lesions
referred with a diagnosis of MIS resulted in change in diagnosis in 11%
of all in situ patients, while change in diagnosis occurred in 7% of in-
vasive melanoma cases. An outside diagnosis of melanoma in situ was
most commonly upstaged to invasive melanoma. The change in diag-
nosis led to alterations in expected prognosis and in the recommended
excision margins and SNB indications. A trend towards thinner and less
invasive melanomas has been observed [4]. Of new cases diagnosed,
70% are thin melanomas (≤1mm) [5]. Currently, most multi-
disciplinary melanoma care focuses on patients with advanced disease
while patients with early-stage melanomas may be potentially over-
looked [3]. According to our study, referral of MIS and thin melanoma
histopathologic material to a second expert histopathology review may
also be of particular benefit to establish correct diagnosis and staging.
Our study has several limitations. First, pathologic stage could be
affected after expert review of recut slides as Breslow depth may be
changed in recut sections. In this study, however, the original slide was
requested from the reference laboratory. Second, interobserver varia-
tion in the histopathologic reporting of melanoma affects staging.
Several studies have shown that despite the existence of well-estab-
lished criteria for the diagnosis and microscopic staging of melanocytic
lesions, there is still considerable disagreement among pathologists
when faced with actual histologic specimens [9].
6. Conclusion
Our data demonstrate that review of melanoma by an expert
Table 3
Changes in Breslow thickness (> 0.3mm and ≤0.3mm).
1st diagnosis/
Breslow thickness
(mm)
Breslow thickness
after 2nd review
Age/
years
Location
Women (n= 13,
5%)
0.9 1.5 74 shoulder
1.0 1.9 54 leg
in situ 3.0 60 foot
1.0 0.6 48 back
1.2 3.5 67 toe
1.1 1.5 82 back
in situ 0.4 76 back
0.3 0.9 65 arm
0.4 1.0 76 thigh
0.4 0.9 45 arm
in situ 0.5 22 abdomen
in situ 0.7 71 back
0.6 1.1 77 knee
Men (n= 9, 3%) 1.5 2.1 69 abdomen
in situ 0.9 78 shoulder
0.9 1.3 63 chest wall
0.5 0.9 48 abdomen
in situ 1.1 66 back
0.5 0.9 59 chest wall
6.0 10.5 50 leg
2.0 3.2 52 finger
0.5 0.1 57 back
Women (n= 3,
1%)
0.9 1.1 32 back
0.5 0.7 72 back
in situ 0.3 91 arm
Men (n= 2, 1%) in situ 0.3 27 back
in situ 0.2 71 abdomen
Table 4a
Change in AJCC tumor staging after a second expert pathology review of 27
cases with changes in Breslow thickness.
Tumor Stage Referral pathology
tumor stage
Tumor board pathology
tumor stage
n (%) n (%)
Tis (MIS) 9 (33) 1 (4)
T1A (< 0.8mm, no ulceration) 12 (45) 14 (52)
T1B (< 0.8mm, ulceration) 1 (4) 0 (0)
T2A (> 1.0–2.0mm, no
ulceration)
3 (11) 7 (26)
T2B (> 1.0–2.0mm,
ulceration)
0 (0) 1 (4)
T3A (> 2.0–4.0mm, no
ulceration)
2 (7) 4 (14)
Abbreviations: AJCC, American Joint Committee on Cancer; MIS, melanoma in
situ.
Table 4b
Changes in staging groups after a second expert pathology review of 27 cases
with changes in Breslow thickness.
Change in staging Number of cases (%)
Tis to T1a 7 (26)
Tis to T2a 1 (4)
Tis to T3a 1 (4)
T1a to T2a 4 (15)
T1a to Tis 1 (4)
T1b to T2b 1 (4)
T2a toT3a 1 (4)
No change in stage 11 (41)
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dermatopathologist results in frequent, clinically meaningful altera-
tions in diagnosis, staging, and surgical treatment. The confirmation of
a cancer diagnosis should be the first step in the initiation of treatment
especially in patients younger than 40 years old and in early-stage
melanomas.
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